Konstantinos N Aronis1, Jonathan L Thigpen2, Yorghos Tripodis3, Chrisly Dillon4, Kristen Forster5, Lori Henault6, Emily Kate Quinn3, Peter B Berger5, Nita A Limdi3, Elaine M Hylek6. 1. Department of Medicine, Boston Medical Center, Boston University, 801 Massachusetts Avenue, Crosstown 2, Boston, MA 02118 USA. Electronic address: konstantinos.aronis@bmc.org. 2. Department of Pharmacy, Notre Dame of Maryland University, Baltimore, MD, USA. 3. Department of Biostatistics, Boston University School of Public Health, Boston, MA USA. 4. Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA. 5. Department of Cardiology, Geisinger Health System, Danville, PA, USA. 6. Department of Medicine, Boston Medical Center, Boston University, 801 Massachusetts Avenue, Crosstown 2, Boston, MA 02118 USA.
Abstract
BACKGROUND AND PURPOSE: Oral anticoagulants are highly efficacious for the prevention of stroke in atrial fibrillation, and are the preferred treatment by current guidelines. The purpose of our study was to assess the utilization of antithrombotic drugs in atrial fibrillation patients at the time of ischemic stroke and the factors associated with their use. METHODS: We enrolled 759 consecutive patients admitted with ischemic stroke at Boston Medical Center, Geisinger Health System, and the University of Alabama. To be eligible, patients had to have electrocardiographically-confirmed atrial fibrillation at the time of admission or within 6 months of the index stroke. All stroke events and electrocardiograms were validated by study physicians. Patients with newly diagnosed atrial fibrillation were not eligible. RESULTS: The mean age was 78 years, 43% were male, 19% black, and the mean CHADS2 score is 3.0. Atrial fibrillation was paroxysmal in 31%. At presentation, 181 (24%) patients were taking warfarin only, 96 (13%) both warfarin and aspirin, 294 (39%) aspirin alone, and 189 (25%) no antithrombotic therapy. The mean international normalized ratio was 1.6. Among patients with paroxysmal atrial fibrillation, one in five was taking warfarin. Although increasing stroke risk was associated with a greater likelihood of warfarin use, only 39% of highest risk CHADS2 3-6 were taking warfarin at the time of stroke. CONCLUSIONS: Among high-risk individuals with atrial fibrillation, only 37% were taking warfarin at the time of stroke. Paroxysmal atrial fibrillation was associated with the highest risk of not receiving warfarin.
BACKGROUND AND PURPOSE: Oral anticoagulants are highly efficacious for the prevention of stroke in atrial fibrillation, and are the preferred treatment by current guidelines. The purpose of our study was to assess the utilization of antithrombotic drugs in atrial fibrillationpatients at the time of ischemic stroke and the factors associated with their use. METHODS: We enrolled 759 consecutive patients admitted with ischemic stroke at Boston Medical Center, Geisinger Health System, and the University of Alabama. To be eligible, patients had to have electrocardiographically-confirmed atrial fibrillation at the time of admission or within 6 months of the index stroke. All stroke events and electrocardiograms were validated by study physicians. Patients with newly diagnosed atrial fibrillation were not eligible. RESULTS: The mean age was 78 years, 43% were male, 19% black, and the mean CHADS2 score is 3.0. Atrial fibrillation was paroxysmal in 31%. At presentation, 181 (24%) patients were taking warfarin only, 96 (13%) both warfarin and aspirin, 294 (39%) aspirin alone, and 189 (25%) no antithrombotic therapy. The mean international normalized ratio was 1.6. Among patients with paroxysmal atrial fibrillation, one in five was taking warfarin. Although increasing stroke risk was associated with a greater likelihood of warfarin use, only 39% of highest risk CHADS2 3-6 were taking warfarin at the time of stroke. CONCLUSIONS: Among high-risk individuals with atrial fibrillation, only 37% were taking warfarin at the time of stroke. Paroxysmal atrial fibrillation was associated with the highest risk of not receiving warfarin.
Authors: Robby Nieuwlaat; Alessandro Capucci; Gregory Y H Lip; S Bertil Olsson; Martin H Prins; Fred H Nieman; José López-Sendón; Panos E Vardas; Etienne Aliot; Massimo Santini; Harry J G M Crijns Journal: Eur Heart J Date: 2006-05-26 Impact factor: 29.983
Authors: Kamakshi Lakshminarayan; Craig A Solid; Allan J Collins; David C Anderson; Charles A Herzog Journal: Stroke Date: 2006-06-29 Impact factor: 7.914
Authors: Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy Journal: J Am Coll Cardiol Date: 2014-03-28 Impact factor: 24.094
Authors: Jakob Raunsø; Christian Selmer; Jonas Bjerring Olesen; Mette Gitz Charlot; Anne-Marie S Olsen; Ditte-Marie Bretler; Jørn Dalsgaard Nielsen; Helena Dominguez; Niels Gadsbøll; Lars Køber; Gunnar H Gislason; Christian Torp-Pedersen; Morten Lock Hansen Journal: Eur Heart J Date: 2011-12-23 Impact factor: 29.983
Authors: M Paciaroni; G Agnelli; V Caso; M Venti; P Milia; G Silvestrelli; L Parnetti; S Biagini Journal: J Thromb Haemost Date: 2005-05-09 Impact factor: 5.824
Authors: Ajay K Kakkar; Iris Mueller; Jean-Pierre Bassand; David A Fitzmaurice; Samuel Z Goldhaber; Shinya Goto; Sylvia Haas; Werner Hacke; Gregory Y H Lip; Lorenzo G Mantovani; Alexander G G Turpie; Martin van Eickels; Frank Misselwitz; Sophie Rushton-Smith; Gloria Kayani; Peter Wilkinson; Freek W A Verheugt Journal: PLoS One Date: 2013-05-21 Impact factor: 3.240
Authors: Frank Cools; Dana Johnson; Alan J Camm; Jean-Pierre Bassand; Freek W A Verheugt; Shu Yang; Anastasios Tsiatis; David A Fitzmaurice; Samuel Z Goldhaber; Gloria Kayani; Shinya Goto; Sylvia Haas; Frank Misselwitz; Alexander G G Turpie; Keith A A Fox; Karen S Pieper; Ajay K Kakkar Journal: J Thromb Haemost Date: 2021-07-23 Impact factor: 5.824